Safety and immunogenicity of heat-treated zoster vaccine (ZVHT) in immunocompromised adults

Abstract

Background. Safety and immunogenicity of heat-treated zoster vaccine (ZVHT) were assessed in immunocompromised adults.Methods. In a randomized, double-blind, placebo-controlled, multicenter study, 4 doses ZV HT or placebo were administered approximately 30 days apart to adults with either solid tumor malignancy (STM); hematologic malignancy (HM); human immunodeficiency virus (HIV) with CD4+ ≤200; autologous hematopoietic stem-cell transplant (HCT) or allogeneic-HCT recipients. Varicella-zoster virus (VZV) T-cell responses by interferon-γ enzyme-linked immunospot (IFN-γ ELISPOT) and VZV antibody concentrations by glycoprotein enzyme-linked immunosorbent assay (gpELISA) were measured at baseline and approximately 28 days after each dose.Results. No safety signals were found in any group. IFN-γ ELISPOT geometric mean fold rises (GMFR) after dose 4 in STM, HM, HIV, and autologous-HCT patients were 3.00 (P